BioTherapeutics in new national AtheroNeth consortium
The Dutch Heart Foundation will fund a new nation-wide consortium, AtheroNeth, consisting of preclinical and clinical scientists in the field of atherosclerosis research. AtheroNeth aims to identify novel biomarkers that can be applied to stratify patient groups at risk for acute cardiovascular events and to improve treatment strategies. The Dutch Heart Foundation will invest 6 million Euro in total.
From the division of BioTherapeutics, Amanda Foks, Bram Slütter, and Ilze Bot will participate as work package leader in this consortium of national experts and will investigate immune cell populations that associate with unstable atherosclerosis. They will do so by using human atherosclerosis samples and by performing in vivo intervention studies. This novel consortium will be part of the Dutch CardioVascular Alliance Network and will have a duration of 5 years. Amanda, Bram and Ilze look forward to contributing to this challenging project!
Link to Dutch Heart Foundation announcement: https://professionals.hartstichting.nl/actualiteiten/nieuw-consortium-voor-persoonlijke-behandeling-bij-slagaderverkalking
